Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 16,851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Symptom Clusters Clear all
Completed No phase listed Observational Accepts healthy volunteers

Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

NCT00001210
View directory record Official record
Conditions
HIV Infections, Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 2 Interventional Results available

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

NCT02332980
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 10, 2026, 2:57 PM EST
Not listed Not applicable Interventional

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

NCT00988780
View directory record Official record
Conditions
Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
Interventions
maraviroc, Placebo
Drug
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Nov 10, 2026, 2:57 PM EST
Active, not recruiting Phase 3 Interventional

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Centennial, Colorado • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 10, 2026, 2:57 PM EST
Recruiting No phase listed Observational

Molecular Genetics of Heterotaxy and Related Congenital Heart Defects

NCT02432079
View directory record Official record
Conditions
Heterotaxy Syndrome, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 10, 2026, 2:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band

NCT05396196
View directory record Official record
Conditions
Myofascial Trigger Point Pain
Interventions
Kinesio® Tape
Device
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 10, 2026, 2:57 PM EST
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

NCT00003827
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
amifostine trihydrate, cytarabine, topotecan hydrochloride
Drug
Lead sponsor
ALZA
Industry
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

HIV Prevention in Haitian American Adolescents

NCT00494273
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive Behavioral and Standard Care with Healthy Living
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
14 Years to 17 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Nov 10, 2026, 2:57 PM EST
Completed Not applicable Interventional

Effects of Upper Airway Muscle Training on OSA

NCT02502942
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Upper Airway Muscle Exercise, Sham Exercise
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 79 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Nov 10, 2026, 2:57 PM EST
Recruiting Not applicable Interventional

Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder

NCT05499741
View directory record Official record
Conditions
Tourette's Disorder, Insomnia
Interventions
Forehead Temperature-Regulating Therapy
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Nov 10, 2026, 2:57 PM EST
Completed No phase listed Observational

Electrical Impedance Imaging of Patients on Mechanical Ventilation

NCT02232841
View directory record Official record
Conditions
Pneumothorax, Pulmonary Contusion, Pleural Effusion, Pulmonary Edema, Atelectasis, Hyperinflation, Emphysema, Acute Respiratory Distress Syndrome
Interventions
Mechanical Ventilation, CT Scan
Device
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 2 Interventional

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

NCT00098683
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
amifostine trihydrate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
74
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 10, 2026, 2:57 PM EST
Completed No phase listed Observational

Genetic Determinants of Congenital Heart Disease Outcomes

NCT01656941
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Hypoplastic Right Heart Syndrome, d-Transposition of the Great Arteries
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Up to 30 Days
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Nov 10, 2026, 2:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

NCT00026754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Sarcoma, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month and older
Enrollment
19,522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 10, 2026, 2:57 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome

NCT01399138
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Blueberry Powder
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Nov 10, 2026, 2:57 PM EST
Completed Not applicable Interventional

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

NCT00002269
View directory record Official record
Conditions
HIV Infections
Interventions
Ampligen, Zidovudine
Drug
Lead sponsor
HEM Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Miami, Florida • Portland, Oregon • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 10, 2026, 2:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders

NCT02836405
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Nov 10, 2026, 2:57 PM EST
Active, not recruiting Not applicable Interventional Results available

Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components

NCT05318183
View directory record Official record
Conditions
PreDiabetes, Dysbiosis, Endotoxemia, Inflammation
Interventions
Whole Wheat Bread, White Bread (control)
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 2 Interventional

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

NCT01703533
View directory record Official record
Conditions
Rett Syndrome
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 10, 2026, 2:57 PM EST
Terminated No phase listed Observational

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

NCT04356443
View directory record Official record
Conditions
Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions
AirGo Respiratory Monitor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 2 Interventional Results available

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

NCT00079391
View directory record Official record
Conditions
Hematologic Malignancies, Bone Marrow Transplant Rejection
Interventions
allogeneic hematopoietic stem cell transplantation
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Nov 10, 2026, 2:57 PM EST
Enrolling by invitation Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 10, 2026, 2:57 PM EST
Completed Phase 4 Interventional Results available

Oxygen Versus PAP for Sleep Apnea in Heart Failure

NCT01807897
View directory record Official record
Conditions
Heart Failure, Sleep Apnea Syndromes
Interventions
Continuous positive airway pressure, Nocturnal supplemental oxygen, Healthy Lifestyle and Sleep Education
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Nov 10, 2026, 2:57 PM EST